目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T10531 | EGFR VEGFR FLT Src | ||
BGB-102 (JNJ-26483327) 是一种针对FLT3 和 YES1 的激酶抑制剂和 针对 EGFR 和 VEGFR3 的拮抗剂,可用于研究黄斑变性和与遗传病与畸形相关的疾病。 | |||
T1452 | VEGFR PDGFR c-Kit | ||
Axitinib (AG-013736) 是一种多靶点酪氨酸激酶抑制剂,能够抑制 VEGFR1 (IC50:4 nM),VEGFR2 (IC50:20 nM),VEGFR3 (IC50:0.4 nM),PDGFRβ (IC50:2 nM)。 | |||
T15185 | VEGFR FGFR | ||
Lucitanib (E-3810) 是 VEGFR 和 FGFR 的双重抑制剂,有效和选择性地抑制VEGFR1 (IC50:7 nM),VEGFR2 (IC50:25 nM),VEGFR3 (IC50:10 nM),FGFR1 (IC50:17.5 nM),FGFR2 (IC50:82.5 nM)。 | |||
T6720 | Apoptosis VEGFR PDGFR | ||
Vatalanib dihydrochloride (PTK787 dihydrochloride) 是一种VEGFR2/KDR 的抑制剂,其IC50值为37nM。 | |||
T6930 | c-Fms VEGFR FGFR PDGFR c-Kit Autophagy | ||
Pazopanib Hydrochloride (Votrient HCl) 是一种多靶点抑制剂,抑制 VEGFR1、VEGFR2、VEGFR3、PDGFRβ、c-Kit、FGFR1和c-Fms 的IC50分别为10、30、47、84、74、140和146 nM。 | |||
T0520 | VEGFR FGFR c-RET PDGFR c-Kit | ||
Lenvatinib (E7080) 是一种多靶点受体酪氨酸激酶抑制剂,抑制 VEGFR1-3、FGFR1-4、KIT、PDGFR 和 RET 等,具有口服活性。Lenvatinib 对 VEGFR2 和 VEGFR3 的抑制活性最强 (IC50=4/5.2 nM)。Lenvatinib 具有强效抗肿瘤活性。 | |||
T1777 | VEGFR FGFR FLT PDGFR Src | ||
Nintedanib (Intedanib) 是一种三重血管激酶抑制剂,抑制 VEGFR1、VEGFR2、VEGFR3 (IC50=34/13/13 nM),FGFR1、FGFR2、FGFR3 (IC50=69/37/108 nM),PDGFRα、PDGFRβ (IC50=59/65 nM)。Nintedanib 具有抗肿瘤活性,通过抑制血管生成来抑制肿瘤生长。 | |||
T0093L | Apoptosis Raf VEGFR FLT Ferroptosis PDGFR c-Kit Autophagy | ||
Sorafenib (Bay 43-9006) 是一种多激酶抑制剂,抑制 Raf-1、B-Raf、VEGFR2、VEGFR3、VEGFR4、PDGFRβ、FLT3、c-Kit 等 (IC50=6/22/90/15/20/20/57/58 nM),具有口服活性。Sorafenib 具有抗肿瘤活性,可以诱导细胞自噬和凋亡,也可以激动铁死亡。 | |||
T5001 | VEGFR FGFR PDGFR | ||
Nintedanib esylate (BIBF 1120 esylate) 是一种有效的三重血管激酶抑制剂,能够抑制 VEGFR1 (IC50:34 nM)、VEGFR2 (IC50:13 nM)、VEGFR3 (IC50:13 nM),FGFR1 (IC50:69 nM)、FGFR2 (IC50:37 nM)、FGFR3 (IC50:108 nM),PDGFRα (IC50:59 nM)、PDGFRβ (IC50:65 nM)。 | |||
T1792L | Raf VEGFR c-RET PDGFR c-Kit Autophagy | ||
Regorafenib monohydrate 是一种新型口服多激酶抑制剂,对VEGFR1/2/3、PDGFRβ、Kit、RET 和Raf-1的IC50分别为 13、4.2、46、22、7、1.5 和 2.5 nM。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-01936 | VEGFR3/FLT4 Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-00949 | VEGFR3/FLT4 Protein, Human, Recombinant (His) | Human | HEK293 | ||
Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-01937 | VEGFR3/FLT4 Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 | ||
Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPK-00445 | VEGFR3/FLT4 Protein, Human, Recombinant (His & Avi) | Human | HEK293 | ||
Vascular endothelial growth factor (VEGF) and its receptors VEGF-R1, -R2 and -R3 play important roles in tumor angiogenesis and are associated with poor prognosis in several solid tumors.VEGF-R1, -R2 and -R3 were highly expressed in CRC cells and stromal vessels. VEGF-R1 strong positive staining correlated with shorter survival after CRC surgery.
|
|||||
TMPY-01069 | VEGFR3/FLT4 Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPK-00446 | VEGFR3/FLT4 Protein, Human, Recombinant (aa 25-776, His & Avi), Biotinylated | Human | HEK293 | ||
Vascular endothelial growth factor (VEGF) and its receptors VEGF-R1, -R2 and -R3 play important roles in tumor angiogenesis and are associated with poor prognosis in several solid tumors.VEGF-R1, -R2 and -R3 were highly expressed in CRC cells and stromal vessels. VEGF-R1 strong positive staining correlated with shorter survival after CRC surgery.
|
|||||
TMPY-06620 | VEGFR3/FLT4 Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 | ||
Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|